Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Differentiated Thyroid Gland Carcinoma”

65 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 65 results

Not applicableUnknownNCT04858867
What this trial is testing

Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)

Who this might be right for
Differentiated Thyroid Cancer
Leiden University Medical Center 12
Testing effectiveness (Phase 2)Study completedNCT00381641
What this trial is testing

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Who this might be right for
Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaRefractory Thyroid Gland Carcinoma+16 more
National Cancer Institute (NCI) 63
Testing effectiveness (Phase 2)Study completedNCT02702388
What this trial is testing

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

Who this might be right for
Thyroid Cancer
Eisai Inc. 241
Testing effectiveness (Phase 2)Study completedNCT01270321
What this trial is testing

Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer

Who this might be right for
Thyroid Cancer
Emory University 42
Testing effectiveness (Phase 2)UnknownNCT04554680
What this trial is testing

Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

Who this might be right for
Thyroid Cancer
National University Hospital, Singapore 5
Not applicableStudy completedNCT02764554
What this trial is testing

Post-Marketing Surveillance of Lenvima in Korean Patients

Who this might be right for
Differentiated Thyroid Carcinoma (DTC)
Eisai Korea Inc. 132
Testing effectiveness (Phase 2)Active Not RecruitingNCT03914300
What this trial is testing

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Gland CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaPoorly Differentiated Thyroid Gland Carcinoma+6 more
National Cancer Institute (NCI) 11
Early research (Phase 1)Active Not RecruitingNCT04514484
What this trial is testing

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Who this might be right for
Advanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular Carcinoma+60 more
National Cancer Institute (NCI) 8
Not applicableActive Not RecruitingNCT04970134
What this trial is testing

Spanish Study for Molecular Characterization of Thyroid Carcinoma

Who this might be right for
Differentiated Thyroid CarcinomaMedullary Thyroid Carcinoma
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello 150
Testing effectiveness (Phase 2)Study completedNCT01208051
What this trial is testing

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Who this might be right for
Refractory Differentiated Thyroid Gland CarcinomaRefractory Thyroid Gland Follicular CarcinomaRefractory Thyroid Gland Hurthle Cell Carcinoma+2 more
National Cancer Institute (NCI) 127
Testing effectiveness (Phase 2)Active Not RecruitingNCT03449108
What this trial is testing

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Who this might be right for
Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone+13 more
M.D. Anderson Cancer Center 30
Post-approval studies (Phase 4)Study completedNCT03573960
What this trial is testing

Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

Who this might be right for
Thyroid Neoplasms
Eisai Pharmaceuticals India Pvt. Ltd 50
Testing effectiveness (Phase 2)Study completedNCT02244463
What this trial is testing

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Who this might be right for
Anaplastic Thyroid CancerThyroid CancerDifferentiated Thyroid Cancer
Dana-Farber Cancer Institute 46
Not applicableUnknownNCT06062563
What this trial is testing

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Who this might be right for
Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
Peking Union Medical College Hospital 10
Testing effectiveness (Phase 2)UnknownNCT02041260
What this trial is testing

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Who this might be right for
Differentiated Thyroid Cancer (DTC)Poorly Differentiated Thyroid Cancer
Thomas Jefferson University 43
Testing effectiveness (Phase 2)Study completedNCT02614495
What this trial is testing

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

Who this might be right for
Thyroid Carcinoma
Hutchison Medipharma Limited 66
Early research (Phase 1)Study completedNCT01413113
What this trial is testing

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

Who this might be right for
Recurrent Thyroid CancerStage IVA Follicular Thyroid CancerStage IVA Papillary Thyroid Cancer+4 more
University of Washington 6
Large-scale testing (Phase 3)UnknownNCT03048877
What this trial is testing

Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Peking Union Medical College Hospital 118
Testing effectiveness (Phase 2)Study completedNCT03244956
What this trial is testing

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

Who this might be right for
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
Gustave Roussy, Cancer Campus, Grand Paris 40
Early research (Phase 1)Study completedNCT04462471
What this trial is testing

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Who this might be right for
Thyroid CarcinomaThyroid CancerThyroid Cancer, Follicular+3 more
Memorial Sloan Kettering Cancer Center 8
Next Page